Fruquintinib and Everolimus
2023-013-CH01 IIT-RCC
Unknown small_molecule active
Quick answer
Fruquintinib and Everolimus for Renal Cell Carcinoma, Clear Cell, Somatic is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Renal Cell Carcinoma, Clear Cell, Somatic
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active